rss.nicho @GiadaNicholas - Twitter Profile

Pinned Tweet

11 months ago

$ABCL AbCellera – a true diamond I love technical analysis. I’ve spent years mastering indicators, reading charts, recognizing patterns. But no matter how precise it is, technicals will always come second to instinct. When I first found AbCellera ($ABCL), I was just curious. I didn’t invest a cent—not until I started digging deeper. I discovered Carl Hansen, the CEO. A brilliant scientist with unmatched passion. He once spent a week in Dr. James’ lab and completed more experiments than their best student would in a year, creating Fluidigm’s first commercial product. Carl isn’t just running a company—he’s building a legacy. AbCellera’s silence on social media frustrated me at first. But after a year of watching, I get it. They don’t talk. They execute. I kept digging. They helped DARPA deliver a COVID antibody, partnered with Lilly, secured Canadian government funding, built state-of-the-art facilities, amassed huge cash reserves, and filed unique microfluidics patents (recently defended successfully in court). Their GMP manufacturing site goes live this year. How many biotechs can say the same? Then I looked at the chart. From $60 to $2. The market punished them for lack of revenue, not realizing they were quietly transforming into a company that could rival Big Pharma. As an entrepreneur, I get it. My first store thrived, then struggled. I reinvested, expanded, and now I’m in a place I never imagined. AbCellera is doing the same. They’ve been underestimated because few realized how much they were restructuring to achieve 100x what they did when shares were $40. Insiders buying at $2.16 and $3.24 shows confidence from those who know more than any of us. Institutions went from 40% to 60% ownership in months. I’m no institution. I’m just a retail investor who went all-in on Carl Hansen. And yes, I once dreamt of Carl. At $2 he smiled and said, “Great things are coming.” That’s the Carl I feel in my gut. My all-in bet will pay off. AbCellera isn’t a meme stock. It’s not a penny stock. It’s a biotech titan in the making. I’m already smiling at the thought of $20… $30… $40.

GiadaNicholas's tweet photo. $ABCL AbCellera – a true diamond

I love technical analysis.
I’ve spent years mastering indicators, reading charts, recognizing patterns. But no matter how precise it is, technicals will always come second to instinct.
When I first found AbCellera ($ABCL), I was just curious. I didn’t invest a cent—not until I started digging deeper.

I discovered Carl Hansen, the CEO. A brilliant scientist with unmatched passion. He once spent a week in Dr. James’ lab and completed more experiments than their best student would in a year, creating Fluidigm’s first commercial product.

Carl isn’t just running a company—he’s building a legacy.
AbCellera’s silence on social media frustrated me at first. But after a year of watching, I get it. They don’t talk. They execute.

I kept digging.
They helped DARPA deliver a COVID antibody, partnered with Lilly, secured Canadian government funding, built state-of-the-art facilities, amassed huge cash reserves, and filed unique microfluidics patents (recently defended successfully in court). Their GMP manufacturing site goes live this year. How many biotechs can say the same?
Then I looked at the chart. From $60 to $2. The market punished them for lack of revenue, not realizing they were quietly transforming into a company that could rival Big Pharma.

As an entrepreneur, I get it. My first store thrived, then struggled. I reinvested, expanded, and now I’m in a place I never imagined.
AbCellera is doing the same. They’ve been underestimated because few realized how much they were restructuring to achieve 100x what they did when shares were $40.

Insiders buying at $2.16 and $3.24 shows confidence from those who know more than any of us. Institutions went from 40% to 60% ownership in months.

I’m no institution. I’m just a retail investor who went all-in on Carl Hansen.

And yes, I once dreamt of Carl. At $2 he smiled and said, “Great things are coming.”

That’s the Carl I feel in my gut. My all-in bet will pay off.

AbCellera isn’t a meme stock. It’s not a penny stock.
It’s a biotech titan in the making.
I’m already smiling at the thought of $20… $30… $40.

3

150

11

45

12K

rss.nicho

@GiadaNicholas

Who to follow

Last Seen Users on Sotwe

Trends for you

Most Popular Users